Finanzwire Finanzwire
Basculer en Français
11166 Companies
246602 Keywords
174550 Articles
133185 Press releases
Headlines Articles Press releases Biocon Remove
  1. Home
  2. Companies
  3. Biocon
Finanzwire
Basculer en Français
Headlines Articles Press releases

News

  • BRIEF

    published on 09/22/2026 at 14:07, 21 days 1 hour ago

    Biocon's Pertuzumab Biosimilar Secures EMA CHMP Approval Recommendation

    Biosimilar Breast Cancer EMA Approval Pertuzumab Biocon
  • PRESS RELEASE

    published on 09/22/2026 at 14:02, 21 days 1 hour ago

    Biocon's Pertuzumab Becomes First Biosimilar to Secure EMA CHMP Approval Recommendation Under New Tailored Clinical Approach

    Biocon's Pertuzumab, the first biosimilar to secure EMA CHMP approval, marks a milestone in biosimilar science, granting access to HER2-positive breast cancer treatment in Europe
    Biosimilar Breast Cancer Pertuzumab Biocon EMA CHMP Approval
    Logo of Biocon
  • BRIEF

    published on 03/27/2026 at 10:45, 6 months 17 days ago

    Shreehas Tambe Appointed as CEO & Managing Director of Biocon Limited

    Biopharmaceuticals Global Market Strategy Biocon Leadership Shreehas Tambe Corporate Integration
  • PRESS RELEASE

    published on 03/27/2026 at 10:40, 6 months 17 days ago

    Shreehas Tambe Appointed CEO & Managing Director of Biocon Limited, Effective April 1, 2026

    Shreehas Tambe appointed as CEO & Managing Director of Biocon Limited, leading biosimilars and generics to compete globally. Smooth leadership transition for sustainable growth
    Biosimilars CEO Generics Shreehas Tambe Biocon Limited
    Logo of Biocon
Accesswire
  • Published on 10/13/2026 at 15:00, 17 minutes ago

    Reminder: Today, October 13, 2026, is the Record Date for Jaguar Health's Special Stock Dividend

  • Published on 10/13/2026 at 14:45, 32 minutes ago

    Phase II Clinical Trial of NV-387 Oral Gummies as Treatment of Ebola Progressing Well, Says NanoViricides

  • Published on 10/13/2026 at 14:31, 46 minutes ago

    First Breach Completes First Autonomous Flight of Proprietary Drone Prototype

  • Published on 10/13/2026 at 14:10, 1 hour 7 minutes ago

    NioCorp Places 100% of Its Planned Critical Minerals Production Under Commercial Sales Agreements

  • Published on 10/13/2026 at 14:00, 1 hour 17 minutes ago

    Orogen Royalties Enters into Agreement to Sell the Slaughterhouse Copper-Gold Project to Seabridge Gold

View all ACCESSWIRE
EQS Group
  • Published on 10/13/2026 at 15:06, 11 minutes ago

    Form 8.3 - The Vanguard Group, Inc.: Prologis, Inc.

  • Published on 10/13/2026 at 15:05, 12 minutes ago

    Form 8.3 - The Vanguard Group, Inc.: RHI Magnesita N.V.

  • Published on 10/13/2026 at 15:05, 12 minutes ago

    Graylog v7.2 launches the Verascend™ Incident System, transforming how security teams detect and respond to threats

  • Published on 10/13/2026 at 15:03, 13 minutes ago

    Form 8.3 - The Vanguard Group, Inc.: Permanent TSB Group Holdings plc

  • Published on 10/13/2026 at 15:02, 15 minutes ago

    Form 8.3 - The Vanguard Group, Inc.: DCC plc

View all EQS
Les Echos
  • Published on 10/13/2026 at 09:04, 6 hours 12 minutes ago

    Peru Is Recognized as “South America's Leading Destination” at the World Travel Awards

  • Published on 10/12/2026 at 17:59, 21 hours 18 minutes ago

    Reporting on share buyback transactions carried out between October 7 and October 9, 2026

  • Published on 10/12/2026 at 17:45, 21 hours 32 minutes ago

    Weekly share buyback

  • Published on 10/12/2026 at 17:45, 21 hours 32 minutes ago

    Declaration of transactions on own shares from October 5, 2026 to October 11, 2026

  • Published on 10/12/2026 at 15:47, 23 hours 29 minutes ago

    Statement about the number of shares composing the share capital and the number of voting rights as of September 30, 2026

View all LES ECHOS COMFI WIRE

With finanzwire.com, you can follow all the latest financial news in real time from the best sources for companies listed on the Paris, Brussels, Amsterdam, Lisbon, Frankfurt and New York stock exchanges. You'll have access to summary articles written by us and press releases published by the companies themselves.

Finanzwire

87, rue Ordener - 75018 Paris

Contact us

+33 1 42 23 83 61

© 2026 Finanzwire

Contact Authors Cookies policy Terms and conditions Privacy policy